Competition Commission audit reforms — not as strict as first anticipated
The Competition Commission (CC) has been concerned about the lack of competition in the audit market for some time. It reports that this lack is due to factors that inhibit companies from switching auditors and the incentives auditors are having to focus on satisfying management rather than shareholder needs. The CC Final Report (published on 25 October 2013) confirms the CC position that all FTSE 350 companies must put their statutory audit engagement out to tender at least every 10 years — no company will be able to delay beyond 10 years.
This is a retreat from the previously contentious position that audit contracts should be tendered every five years. As a compromise, the CC has confirmed that companies should consider going out to tender every five years and if they choose not to at that time the Audit Committee will be required to report the year it plans to conduct the tender and confirm why that is in the best interest of shareholders…
If you are registered and logged in to the site, click on the link below to read the rest of the Wragge & Co briefing. If not, please register or sign in with your details below.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Wragge Lawrence Graham & Co
News from The Lawyer
Briefings from Wragge Lawrence Graham & Co
Ruling on an application for specific disclosure could have big implications in the early stages of procurement disputes.
Hospira v Genentech III: Swiss form claim obvious in view of paper reporting the existence of Phase III trial
Arnold J has delivered the latest blow in the ongoing saga surrounding trastuzumab (the monoclonal antibody in Herceptin) and Hospira’s continued efforts to knock out Genentech’s patents.